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Abstract
               Genetically engineered pacemakers could be a possible alternative to implantable 
electronic devices for the treatment of bradyarrhythmias. The strategies include upregulation of 
beta adrenergic receptors, conversion of myocytes into pacemaker cells and stem cell therapy. 
Pacemaker activity in adult ventricular myocytes is normally repressed by the inward rectifier 
potassium current (IK1). The IK1 current is encoded by the Kir2 gene family. Use of a negative 
construct that suppresses current when expressed with wild-type Kir2.1 is an experimental 
approach for genesis of genetic pacemaker. hyperpolarisation activated cyclic nucleotide gated 
(HCN) channels which generate If current, the pacemaker current of heart can be delivered to 
heart by using stem cell therapy approach and viral vectors. The unresolved issues include 
longevity and stability of pacemaker genes, limitations involved in adenoviral and stem cell 
therapy and creation of genetic pacemakers which can compete with the electronic units.
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Introduction
              
               Implantable electronic pacemakers remain the treatment of choice for high degree 
atrioventricular blocks and sinus node dysfunction. The shortcomings of electronic pacemakers 
include limited battery life, need for lead implantation into heart and lack of response to 
autonomic and physiologic demands on the heart.  Molecular approaches to the development of a 
biological pacemaker are a conceptually attractive alternate treatment modality for heart blocks. 
The approaches attempted to provide such pacemaker function   include up regulation of β2 
adrenergic receptors1, down regulation of K+ current IK1
2  and over expression of HCN2 
(hyperpolarisation activated cyclic nucleotide gated) channels the molecular correlate of the 
endogenous cardiac pacemaker current If  3. The genetic treatment can be applied to heart by 
plasmid injection, use of viral constructs or stem cell therapy4,5.                                     
Molecular targets for genesis of biological pacemaker                                                   
β2 adrenergic receptors                                                                  
            The sinus node has a higher density of β adrenergic receptors (βAR) compared with 
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surrounding atrium1. This density of βAR and its regulation of If current suggest that increases in 
the density of βAR in the vicinity of the sinus node may lead to an increase in heart rate. The up 
regulation of β2 adrenergic receptors can be achieved by plasmid injection into heart. It was 
noted that after injection of plasmids in porcine right atrium heart rates were 50% faster than 
those of controls. One potential limitation of this strategy is that the diseased endogenous cardiac 
pacemaker mechanisms are left intact and the β2 receptor is used as a nonspecific stimulator of 
heart rate. It can influence other catecholamine sensitive channels also.                               
HCN   channel   and   If  current                                                          
                  Action potential of pacing cells is unique in that they have a slow depolarizing phase, 
rendering them spontaneously active6.  The depolarization involves interaction between HCN 
channels and L & T type calcium channels. The modification of these channels is a therapeutic 
target.
            HCN channels generate If current which contribute to genesis of pacemaker activity. If 
channel is activated on membrane hyperpolarisation rather than on depolarization7. It has four 
fold selectivity for K+ than Na+. The typical features of If  current include activation by 
hyperpolarized membrane potential, conduction of Na+ and K+, modulation by cyclic adenosine 
monophospate (CAMP) and blockade by cesium (Cs+)8. HCN generated current also has the 
above features. Four different HCN genes have been identified9. HCN1 is the most rapidly acting 
channel, HCN4 the slowest with HCN2 and 3 possessing intermediate kinetics10. HCN1, 2 and 4 
have been found to express in adult heart, HCN4 being the most highly expressed one in SA 
node.   HCN2   expression   was   noted   in   atrium,   ventricle   and   SA   node.
            HCN can be delivered to heart by adenoviral construct or using stem cells. The nucleic 
acids delivered by adenoviruses do not integrate into genome as they are episomal. Stem cell 
therapy may be more promising than viral strategy. The approach using HCN may be less 
problematic and proarrythmic as it incorporates the endogenous pacemaker channel gene, which 
selectively   activates   only   during   diastole14.                                   
Inward Rectifier Potassium Current (IK1)  
               IK1  and  other   background   K+  selective  currents   contribute  to  action  potential 
depolarization and establish diastolic resting membrane potential. Down regulation of the 
background K+ current IK1 is one of the approaches attempted to provide pacemaker function. 
Genetic suppression of IK1 can converts quiescent myocytes into pacemaker cells.               
            IK1 is the classical inward rectifier potassium current. Inwardly rectifying K+ channels 
(Kir) are responsible for stabilizing the resting membrane potential. Inward rectification is a 
phenomenon in which conductance of a Kir channel increases with hyperpolarisation but 
decreases with depolarization. Rectification in Kir channels results from voltage dependent 
channel block by intracellular cations12. IK1 is absent or poorly expressed in sinus and AV nodal 
cells. Native IK1 in human ventricular myocytes is reduced by adrenergic receptor stimulation.
            It was observed that a dominant negative strategy to reduce IK1, which usually maintain 
ventricular myocytes at negative membrane potentials, induced spontaneous impulse initiation in 
guinea pig heart. The inward rectifier potassium current is encoded by Kir2 gene family. 
Replacement of 3 amino acid residues in the pore structure of Kir2.1 creates a dominant negative 
construct12. Downregulation of IK1 removes an important determinant of repolarisation leading 
to prolonged repolarisation in cells lacking this current13. This may result in excessive dispersion 
of repolarisation leading to theoretical risk of proarrhythmia.                                                 
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Stem cell therapy                                                                                                                             
            Human embryonic stem cells can be used to create pacemakers or adult mesenchymal 
stem cells may be used as platforms for delivery of pacemaker genes to myocardium. The 
advantage of these cells includes their ability to make functional gap junctions and generate 
spontaneous rhythms15. The approach using embryonic stem cells carry the problems of 
identifying appropriate cell lineages, possibility of stem cell differentiation into lines other than 
pacemaker cells, and potential for neoplasia. Adult mesenchymal stem cells are biologically inert 
vectors which can deliver genetic information to myocardium. Human mesenchymal stem cells 
(hMSCs) as a platform for delivery of genes into heart is a more attractive option because they 
can be obtained in large numbers, easily expanded in culture, capable of long term transgene 
expression   and   their   administration   can   be   autologous   or   via   banked   stores15.           
Gene therapy versus stem cell therapy                                                     
            In gene therapy a cardiac myocyte is converted into a pacemaker cell whereas in stem 
cell therapy myocytes retain their original function. An inherent problem of gene therapy is use 
of viruses. Replication deficient adenoviruses with little infectious potential lead to only transient 
improvement in pacemaker function. Retroviruses may be carcinogenic and infective.                  
Important studies on biological pacemakers                                               
1. Molecular transfer of the human β2 Adrenergic receptor cDNA                                    
            Effects of transferring the human β2 adrenergic receptor were studied by Edelberg JM et 
al1  in chronotropy studies with isolated myocytes, and transplanted as well as endogenous 
murine heart. Murine embryonic cardiac myocytes were transiently transfected with plasmid 
constructs. The total percentage of spontaneously contracting myocytes was greater in β2AR 
transfected cells compared with controls. Also the percentage of myocytes with chronotropic 
rates more than 60 beats per minute was greater in β2AR population than controls. To study the 
ex vivo effects of targeted expression of β2AR a murine neonatal cardiac transplantation model 
was used. Injection of β2AR construct increased the heart rate by 40%. These studies 
demonstrate that local targeting of gene expression may be a feasible modality to regulate the 
cardiac pacemaking activity.                                                                  
2. Local expression of HCN2 in canine left atrium                                             
            Research by Jihong Qu et al13 showed that HCN2 over expression provides an If - based 
pacemaker current sufficient to drive the heart when injected into a localized region of atrium. 
Adenoviral constructs of mouse HCN2 and green fluorescent protein (GFP) or GFP alone were 
injected into LA, terminal studies performed 3-4 days later, myocytes examined for native and 
expressed pacemaker current (If). Spontaneous LA rhythms occurred after vagal stimulation-
induced sinus arrest in 4 of 4 HCN2 + GFP dogs and 0 of 3 GFP dogs (P<0.05).                     
3. Biological pacemaker implanted in canine left bundle branch                                         
            Alexi N. Plotnikov et al14 studied the effect of administration of the HCN2 gene to the 
left bundle branch system of dogs. An adenoviral construct incorporating HCN2 and green 
fluorescent protein (GFP) as a marker was injected via catheter under fluoroscopic control into 
the posterior division of the LBB. Controls were injected with an adenoviral construct of GFP 
alone or saline. During vagal stimulation, HCN2 injected dogs showed rhythms originating from 
the left  ventricle, the rate of  which  was  significantly more rapid than controls.         
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4. Human mesenchymal Stem Cells as a gene delivery system to create cardiac pacemaker    
               Potapova I et  al3  tested the ability of human mesenchymal stem cells to deliver a 
biological pacemaker to the heart. hMSCs transfected with a cardiac pacemaker gene, mHCN2, 
by electroporation expressed current as If - like. They demonstrated that genetically modified 
hMSCs can express functional HCN2 channels in vitro and in vivo, mimicking over exression of 
HCN2 genes in cardiac myocytes, and represent a noval delivery system for pacemaker genes 
into the heart or other electrical syncytia.                                                                   
Limitations of approaches to development of biological pacemaker                           
            Use of viruses to deliver the necessary genes has inherent problems. Replication deficient 
adenoviruses that have little infectious potential lead to only    transient improvement in 
pacemaker function as well as potential inflammatory responses. Retroviruses carry a risk of 
carcinogenicity and infectivity. Limitations of stem cell therapy include immunogenicity of cell, 
the potential for neoplasia, proper engineering of pure cardiac lineages and spatial non 
uniformity of implants. Regulating the level of expression to achieve optimal pacemaker rate is 
critical. Biological pacemaker needs an optimal cell mass and optimal cell-cell coupling for long 
term normal function. Research is ongoing to identify optimal cell numbers and coupling ratios 
needed to optimize the function of biological pacemakers.  
           A major issue is duration of efficacy of biological pacemakers. The duration of pacemaker 
function in approaches using viruses depend on how long the viruses and resulting protein 
constructs survive in the host. To ensure long term function the appropriate delivery system in 
which the construct is effective for long periods must be identified. What will be the longevity 
and   stability   of   next   generation   of   pacemaker   genes?                                        
            The onset of pacemaker function after a pause following the last intrinsic beat is a critical 
factor. Can a pacemaker gene inserted into proximal conduction system create a functioning 
biological pacemaker which can drive the ventricle in demand mode when the sinus node signal 
fails? This requires proper engineering of genes. Considering the cell-cell coupling differences in 
gene therapy and stem cell therapy, the engineering of mutant genes will differ importantly 
between approaches.                                                                                                 
    
            The autonomic responsiveness of biological pacemakers, the ideal site for implantation, 
the extent of recovery of diseased sinus node and the ideal construct to be preferred remain 
unanswered questions. None of the studies tested whether a biological pacemaker could be 
engineered  into the  ventricular  conducting  system.  Will the  functional characteristics  of 
biological pacemakers compete with that of electronic units available?
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